Cyclacel Pharmaceuticals, Inc.
Cyclacel Pharmaceuticals, Inc. (CYCC) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
cycc · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Cyclacel Pharmaceuticals, Inc. (CYCC) measures how much investors pay for each dollar of the company's trailing earnings. CYCC's current PE ratio of N/A is calculated by dividing its stock price of $6.37 by its TTM earnings per share of -$0.57.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Cyclacel Pharmaceuticals, Inc.You CYCC | $11M | N/A | — | -$0.57 |
 Applied Molecular Transport Inc. AMTI | $11M | N/A | — | -$3.23 |
 Apexigen, Inc. APGN | $10M | N/A | — | -$1.59 |
 ESSA Pharma Inc. EPIX | $10M | N/A | — | -$0.64 |
 Gelesis Holdings, Inc. GLS | $12M | N/A | — | -$0.79 |
 IMV Inc. IMVIF | $0M | N/A | — | -$4.37 |
 Korro Bio, Inc. KRRO | $105M | N/A | — | -$12.48 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-1.37 | — | |
2024-12-31 FY2024 | — | $-1.35 | — | |
2023-12-31 FY2023 | — | $-28.28 | — | |
2022-12-31 FY2022 | — | $-28.25 | — | |
2021-12-31 FY2021 | — | $-31.74 | — | |
2020-12-31 FY2020 | — | $-12.67 | — | |
2019-12-31 FY2019 | — | $-9.59 | — | |
2018-12-31 FY2018 | — | $-12.05 | — | |
2017-12-31 FY2017 | — | $-18.61 | — | |
2016-12-31 FY2016 | — | $-68.86 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Cyclacel Pharmaceuticals, Inc. (CYCC) measures how much investors pay for each dollar of the company's trailing earnings. CYCC's current PE ratio of N/A is calculated by dividing its stock price of $6.37 by its TTM earnings per share of -$0.57.
Frequently asked questions
CYCC pe ratio · 6 questionsCYCC's current PE ratio is N/A as of 2026-06-09, based on a stock price of $6.37 and TTM EPS of -$0.57. Data sourced from Financial Modeling Prep via CYCC's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Cyclacel Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09